Please login to the form below

Not currently logged in

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

Gilead Sciences

MacroGenics could receive up to $1bn as part of a new deal with Gilead to research antibodies for four undisclosed targets.

Driving the deal's high value is MacroGenics' promising dual-affinity re-targeting (DART) technology, which Gilead will be hoping to harness in its quest to producing antibody-based therapies that can simultaneously target two different antigens.

The technology's promise has already seen MacroGenics sign a number of pharma deals, tying up with the likes of Boehringer Ingelheim and Servier, and the US-based biotech said it expects the first investigational new drug application for a compound developed using DART to be submitted in late 2013.

The latest agreement involves four targets in total, with Gilead to hold exclusive worldwide rights for three of the programmes.

For the remaining programme, Gilead will hold development and commercialisation rights in North America, Europe, Australia and New Zealand, with MacroGenics retaining rights in all other markets, including Japan, China and Russia.

In financial terms, Gilead will fund research activities in all four programmes in addition to a total of up to $30m in license fee payments and up to $85m in pre-clinical milestone payments.

However, MacroGenics said the total value of the deal could top $1bn if all four programmes achieve the relevant clinical, regulatory and commercialisation milestones.

“We are very pleased to enter this collaboration with Gilead, a world-class biopharmaceutical company committed to the development of innovative therapeutics,” said Dr Scott Koenig, president and CEO of MacroGenics.

“As the fourth major collaboration around our DART platform in the past two years, this deal represents the latest validation of our ongoing efforts."

10th January 2013

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Products come and go, but a pharma company’s most valuable, durable asset is its reputation, writes Duncan Mackenzie-Reid and Simon Grist
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...